Overview

Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma

Status:
Not yet recruiting

Trial end date:
2026-03-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the rate and severity of cytokine release syndrome (CRS) and neurologic events following outpatient administration of axicabtagene ciloleucel in participants with relapsed or refractory (r/r) large B-cell lymphoma (LBCL).

Phase:

Phase 2

Details

Lead Sponsor:

Kite, A Gilead Company

Treatments:

Cyclophosphamide
Dexamethasone
Fludarabine